Insulet (NASDAQ:PODD) Earns “Hold (C)” Rating from Weiss Ratings

Insulet (NASDAQ:PODD)‘s stock had its “hold (c)” rating reiterated by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

PODD has been the subject of a number of other research reports. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Piper Sandler upped their target price on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. JPMorgan Chase & Co. upped their target price on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Finally, Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $346.83.

Insulet Price Performance

PODD stock opened at $315.49 on Wednesday. The stock has a 50-day moving average price of $322.51 and a two-hundred day moving average price of $299.51. Insulet has a 12-month low of $225.37 and a 12-month high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The company has a market cap of $22.21 billion, a PE ratio of 95.89, a price-to-earnings-growth ratio of 2.60 and a beta of 1.40.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the previous year, the business earned $0.55 earnings per share. The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts predict that Insulet will post 3.92 EPS for the current year.

Insider Activity

In related news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently bought and sold shares of the company. Curi Capital LLC raised its stake in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares in the last quarter. Evelyn Partners Investment Management Services Ltd raised its stake in Insulet by 28.7% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after buying an additional 39 shares in the last quarter. Camarda Financial Advisors LLC raised its stake in Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in Insulet by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock valued at $634,000 after buying an additional 45 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV raised its stake in Insulet by 0.6% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after buying an additional 48 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.